PPHE Hotel Group (PPH); announces measures to mitigate COVID-19 pandemic
PPHE Hotel Group is in the process of adopting a set of exceptional operational measures to significantly reduce its costs and help it navigate through the challenging and unprecedented times. These measures include reduced capacity of hotels in Germany and Hungary; the temporary closure of two hotels in Amsterdam and reduced capacity in the rest of the region; the potential temporary closure of around 2,000 rooms in London; steps to reduce payroll including reduced hours, potential reductions in FTEs and the deferral of all 2019 staff incentive payments; and a review into the timing and phasing of the group’s investment programme until markets improve.
Read more...4imprint Group (FOUR); provides Covid-19 update
4imprint expects COVID-19 to adversely impact its revenue and profitability in the current financial year. The company is recalibrating its marketing and activities. It is also identifying and implementing cost saving initiatives, without compromising on long-term business prospects. The daily order counts have been volatile and have fallen to an average over the last three trading days of around 40% of the prior year.
Read more...CentralNic Group (CNIC); announces FY19 revenue of $74.0m
CentralNic Group announced an update on the FY19 performance of Team Internet. Team Internet reported a revenue of $74.0m and an adjusted EBITDA of $12.3m during the period from 1 January 2019 through 24 December 2019. This compares to $66.7m and $10.6m, respectively, reported for the trailing 12 months to 30 June 2019.
Read more...Ergomed (ERGO); announces provisions for COVID-19
Ergomed announced the initiation of a study of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, for the treatment of patients with COVID-19, who have developed serious respiratory complications (Siltuximab In SeriousCOVID-19; SISCO Study). Initial data are expected in late-March 2020.
Read more...EMIS Group (EMIS): final results: results in line with expectations
The company reported in-line results, with growth in revenue and adjusted operating profit maintained at levels similar to those in the half year, along with further strategic progress. Group revenue increased 7% to £159.5m (2018: £149.7m), with recurring revenue growing 4%.
Read more...Rank Group (RNK); announces an update on trading
The Rank Group announced that the company traded well and in line with the guidance issued on 16 January 2020 since the start of H2 of 2019/20 financial year. In the last three weeks, the company witnessed a slowdown in trading across its UK venues and recently, the company inevitably experienced a sharper decline.
Read more...Oxford Biomedica (OXB); expects total revenues for the full year to be c.£65m
Oxford Biomedica announced its trading and business update to 31 December 2019 and post period end review. Revenues from the underlying bioprocessing and commercial development business were, as expected, stronger in H2 compared to H1 and continued to grow in H2 2019 over H2 2018. Cash stood at £16m as of 31 December.
Read more...Osirium Technologies (OSI); wins contract with Ambulance Service
Osirium Technologies has announced a contract win with a major regional UK Ambulance Service. A 60-month term licence for 250 devices for the Osirium PAM platform, including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules, has been purchased by the new client.
Read more...Plant Health Care (PHC); announces admission of 44,602,188
Following the AGM, Plant Health Care announced that the company has made an application to the London Stock Exchange for 44,602,188 new ordinary shares of 1p each to be admitted to trading on AIM pursuant to the placing and subscription. The new ordinary shares will rank pari passu with the existing issued share capital.
Read more...
Shield Therapeutics (STX); announces an update regarding AEGIS-H2H
Shield Therapeutics announced an update and clarification regarding the AEGIS-H2H clinical trial. The data from the trial was primarily designed to be used in health economic analyses, pricing and reimbursement applications as well as marketing purposes.
Read more...